214 related articles for article (PubMed ID: 38788009)
1. Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches.
Alorfi NM; Ashour AM; Alharbi AS; Alshehri FS
Medicine (Baltimore); 2024 May; 103(21):e38245. PubMed ID: 38788009
[TBL] [Abstract][Full Text] [Related]
2. Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Vieira de Castro J; Gomes ED; Granja S; Anjo SI; Baltazar F; Manadas B; Salgado AJ; Costa BM
J Transl Med; 2017 Oct; 15(1):200. PubMed ID: 28969635
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma.
Womeldorff M; Gillespie D; Jensen RL
Neurosurg Focus; 2014 Dec; 37(6):E8. PubMed ID: 25581937
[TBL] [Abstract][Full Text] [Related]
4. Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.
Liu SY; Chiang MF; Chen YJ
Exp Biol Med (Maywood); 2015 Mar; 240(3):315-23. PubMed ID: 25432984
[TBL] [Abstract][Full Text] [Related]
5. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
6. New molecularly targeted therapies for glioblastoma multiforme.
Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
[TBL] [Abstract][Full Text] [Related]
7. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
10. Recurrent glioblastoma multiforme: a review of natural history and management options.
Hou LC; Veeravagu A; Hsu AR; Tse VC
Neurosurg Focus; 2006 Apr; 20(4):E5. PubMed ID: 16709036
[TBL] [Abstract][Full Text] [Related]
11. Molecular advances of brain tumors in radiation oncology.
Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
Rivera M; Bander ED; Cisse B
World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
[TBL] [Abstract][Full Text] [Related]
14. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA targeting as a therapeutic strategy against glioma.
Auffinger B; Thaci B; Ahmed A; Ulasov I; Lesniak MS
Curr Mol Med; 2013 May; 13(4):535-42. PubMed ID: 22934848
[TBL] [Abstract][Full Text] [Related]
17. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
[TBL] [Abstract][Full Text] [Related]
18. Frontiers in the treatment of glioblastoma: Past, present and emerging.
Janjua TI; Rewatkar P; Ahmed-Cox A; Saeed I; Mansfeld FM; Kulshreshtha R; Kumeria T; Ziegler DS; Kavallaris M; Mazzieri R; Popat A
Adv Drug Deliv Rev; 2021 Apr; 171():108-138. PubMed ID: 33486006
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it.
Peschillo S; Caporlingua A; Diana F; Caporlingua F; Delfini R
J Neurointerv Surg; 2016 Oct; 8(10):1078-82. PubMed ID: 26541791
[TBL] [Abstract][Full Text] [Related]
20. Targeting adaptive glioblastoma: an overview of proliferation and invasion.
Xie Q; Mittal S; Berens ME
Neuro Oncol; 2014 Dec; 16(12):1575-84. PubMed ID: 25082799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
